Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)
Blood (2013)
  • Jeff P. Sharman, Cancer Institute
  • Steven E. Coutre, Stanford University
  • Bruce D. Cheson, Georgetown University
  • John M. Pagel, Fred Hutchinson Cancer Research Center
  • Peter Hillmen, St James's University Hospital
  • Jacqueline C. Barrientos, Hofstra University
  • Andrew D. Zelenetz, Memorial Sloan Kettering Cancer Center
  • Thomas J. Kipps, University of California, San Diego
  • Ian Flinn, Sarah Cannon Research Institute
  • Paolo Ghia, Vita-Salute San Raffaele University
  • Herbert Eradat, University of California, Los Angeles
  • Thomas Ervin, Harvard University
  • Nicole Lamanna, Memorial Sloan Kettering Cancer Center
  • Michael Hallek, University of Cologne
  • Bertrand Coiffier, Claude Bernard University Lyon 1
  • Andrew R. Pettitt, Royal Liverpool University Hospital
  • Shuo Ma, Northwestern University
  • Stephan Stilgenbauer, University of Ulm
  • Paula Cramer, University of Cologne
  • Maria Aiello
  • Dave M. Johnson
  • Langdon L. Miller, Pfizer
  • Daniel Li
  • Thomas M. Jahn, Children's Hospital Los Angeles
  • Roger D. Dansey, Wayne State University
  • Susan M. O'Brien, University of Texas MD Anderson Cancer Center
Link
Disciplines
Publication Date
November 15, 2013
Citation Information
Jeff P. Sharman, Steven E. Coutre, Bruce D. Cheson, John M. Pagel, et al.. "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)" Blood Vol. 122 Iss. 21 (2013)
Available at: http://works.bepress.com/john-pagel/116/